Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;1844(4):750-8.
doi: 10.1016/j.bbapap.2014.02.001. Epub 2014 Feb 12.

Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin

Affiliations

Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin

Tamara Staudinger et al. Biochim Biophys Acta. 2014 Apr.

Abstract

A mutant of Mycobacterium smegmatis is a potential class I model substitute for Mycobacterium tuberculosis. Because not all of the rifamycins have been tested in this organism, we determined bactericidal profiles for the 6 major rifamycin derivatives. The profiles closely mirrored those established for M. tuberculosis. Rifalazil was confirmed to be the most potent rifamycin. Because the tuberculous granuloma presents a harshly oxidizing environment we explored the effects of oxidation on rifamycins. Mass spectrometry confirmed that three of the six major rifamycins showed autoxidation in the presence of trace metals. Oxidation could be monitored by distinctive changes including isosbestic points in the ultraviolet-visible spectrum. Oxidation of rifamycins abrogated anti-mycobacterial activity in M. smegmatis. Protection from autoxidation was conferred by binding susceptible rifamycins to tear lipocalin, a promiscuous lipophilic protein. Rifalazil was not susceptible to autoxidation but was insoluble in aqueous solution. Solubility was enhanced when complexed to tear lipocalin and was accompanied by a spectral red shift. The positive solvatochromism was consistent with robust molecular interaction and binding. Other rifamycins also formed a complex with lipocalin, albeit to a lesser extent. Protection from oxidation and enhancement of solubility with protein binding may have implications for delivery of select rifamycin derivatives.

Keywords: Lipocalin-1; Mycobacteria smegmatis; Oxidation; Rifabutin (PubChem CID: 6323490); Rifalazil; Rifalazil (PubChem CID: 6540558); Rifampin (PubChem CID: 24871024); Rifamycin; Rifamycin S (PubChem CID: 6436726); Rifamycin SV (PubChem CID: 6324616); Rifapentine (PubChem CID: 6323497); Rifaximin (PubChem CID: 6436173); Tear lipocalin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Absorbance spectra of six rifamycin drugs at pH 7.3. Rifampin (15 μM) (formula imageformula image), rifapentine (15 μM) (formula image), rifamycin SV (15 μM) (formula image), rifalazil (15 μM) (————), rifaximin (15 μM) (formula image), and rifabutin (30 μM) (formula imageformula image). Inset (A, B): Base chemical structures of all six rifamycin drugs (left) and unique groups (right). The hydroxyls at positions 1 and 4 may be oxidized to form the hydroquinone. The sole hydroxyl of the benzoxanino moiety is a candidate for oxidation on rifalazil. Hydroxyls are not available at position 1 and 4 for autoxidation for rifabutin or rifalazil.
Fig. 2
Fig. 2
Autoxidation of rifamycin drugs at pH 7.3 after various times in phosphate buffer. (a) 1 min, (b) 20 min, (c) 40 min, (d) 80 min, (e) 120 min, (f) 180 min, (g) 24 h. Absorbance spectra of (A) rifampin (15 μM), (B) rifapentine (15 μM), (C) rifamycin SV (15 μM). (D) Mass spectrum of oxidized rifapentine shows predicted monoisotopic m/z of 825.5, 897.2 and 913.1 for the M+H, M+Na and M+K ions.
Fig. 3
Fig. 3
A-D. Oxidation of rifamycin drugs in the presence of tear lipocalin. For comparison, autoxidation of rifamycin drugs alone (-●-), protected with tear lipocalin (100 μM) (-■-), and in the presence of the divalent ion chelator EDTA (5 mM) (-△-). (A) rifampin (15 μM), (B) rifapentine (15 μM), (C) rifamycin SV (15 μM). D-F. Addition of K3Fe(CN)6 to rifamycin drugs protected with tear lipocalin after 180 min at pH 7.3 in phosphate buffer. Absorbance spectra of rifamycin drugs and tear lipocalin (100 μM) after 1 min (————), 180 min (-- -- --), and 180 min with K3Fe(CN)6 (90 μM) (). (E) rifampin (15 μM), (F) rifapentine (15 μM), (G) rifamycin SV (15 μM), (H) rifalazil (15 μM).
Fig. 4
Fig. 4
A. Dissociation constants for rifamycins. *Estimated by gel filtration experiments (profiles shown in Figure S1). B. Ligand binding curve for rifalazil and tear lipocalin determined by spectrophotometric measurement of the soluble complex. The experiment was performed at pH 7.4 in PBS-buffer. The fitting curve is indicated (————).
Fig. 5
Fig. 5
Red shift (solvatochromism) in absorbance spectra taken at successive 2 minute intervals from A to W of rifalazil (30 μM) added to tear lipocalin (100 μM), in 10 mM sodium phosphate, pH 7.3 Inset: Kinetics of solvatochromism, baseline corrected absorbance at 635 nm plotted (black circles) over 40 minutes fits a sigmoidal function (solid line).
Fig. 6
Fig. 6
Influence of antibiotics. Reduced versus oxidized rifamycin drugs. M. smegmatis mc2155 was incubated at pH 7.4 in PBS-buffer with rifamycin drugs (10 μg/ml) for 30 min. Thereafter 150 μl 7H9-G-TW was added and incubated for 48 h. (A) rifampin, (B) rifapentine, (C) rifamycin SV, ( Error bars indicate SD, n = 6.)

Similar articles

Cited by

References

    1. WHO global tuberculosis control report 2010 Summary. Cent Eur J Public Health. 2010;18:237. - PubMed
    1. Aristoff PA, Garcia GA, Kirchhoff PD, Hollis Showalter HD. Rifamycins--obstacles and opportunities. Tuberculosis (Edinb) 2010;90:94–118. - PubMed
    1. Sayada C. Re: Review article titled, “Rifamycins - Obstacles and opportunities” by Paul A. Aristoff, George A. Garcia, Paul D. Kirchhoff, H.D. Hollis Showalter. Tuberculosis. 2010;90(2):94–118. Tuberculosis (Edinb) 2010;90:326; author reply -7. - PubMed
    1. Snapper SB, Melton RE, Mustafa S, Kieser T, Jacobs WR., Jr. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol. 1990;4:1911–9. - PubMed
    1. Alexander DC, Jones JR, Liu J. A rifampin-hypersensitive mutant reveals differences between strains of Mycobacterium smegmatis and presence of a novel transposon, IS1623. Antimicrob Agents Chemother. 2003;47:3208–13. - PMC - PubMed

Publication types

MeSH terms